TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7084029
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acute treatment only)
Study: 27693866
Drug: Other stimulant
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other stimulant use disorder
Study: 11270805
Drug: amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin/clavulanic acid Solutab tablet (500/125)
Study: 11270805
Drug: amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin/clavulanic acid Solutab tablet (500/125) after excluding outliers
Study: 11270805
Drug: Augmentan film‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentan film‐coated tablet (reference)
Study: 11270805
Drug: amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin/clavulanic acid Solutab tablet (intact or dispersed)
Study: 21809439
Drug: Light roast
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light roast coffee (CGA: 4538 μmol/L, NMP: 56 μmol/L)
Study: 14593691
Drug: Immediate multi-family
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate multi-family psychoeducation groups (MFPG) plus treatment as usual
Study: 11069436
Drug: New-users of
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-users of the drug
Study: 11069436
Drug: Drug epidemiology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug epidemiology
Study: 8755685
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/d (increased to 40 mg/d if inadequate response)
Study: 8755685
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg + indomethacin 75 mg/d
Study: 2163421
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice a day
Study: 25234550
Drug: Reference tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablet
Study: 29678772
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose minocycline (200 mg per day)
Study: 17221013
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide
Study: 28338180
Drug: Dezocine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine (0.1 mg/kg in 20 ml infused for 10 min)
Study: 24167370
Drug: 2-dose series
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose series of nonadjuvated monovalent influenza A H1N1 2009 vaccine
Study: 26041682
Drug: ESRA‐C intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESRA‐C intervention delivered via the Internet or tablet at the clinic
Study: 21430075
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of lycopene as a tomato oleoresin for 21 days
Study: 9728734
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg flunitrazepam
Study: 7994508
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg daily to 1.2 mg daily over 14 days)
Study: 7994508
Drug: Dummy medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy medication (placebo)
Study: 28266963
Drug: TV-45070 ointment
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-45070 ointment
Study: 28266963
Drug: TV-45070 ointment
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-45070 ointment in patients with R1150W polymorphism
Study: 28266963
Drug: TV-45070 ointment
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-45070 ointment in wild-type carriers
Study: 10785225
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg/d)
Study: 2952426
Drug: Guar bread
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar bread (100 g guar/kg wheat flour)
Study: 2952426
Drug: Guar granulate
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar granulate (5 g twice daily providing 8.3 g guar/day)
Study: 1894930
Drug: Edoxudine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxudine 3% cream for 5 days
Study: 31521449
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin
Study: 21034626
Drug: Anti-oxidants group
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidants group (vitamin C, vitamin E, Salvia Miltiorrhiza L)
Study: 16181530
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medicine)
Study: 9350363
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plain (2 mg.kg‐1) - Wound infiltration (Group A)
Study: 9350363
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plain (2 mg.kg‐1) - Regional nerve blockade (Group B)
Study: 9350363
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plain (2 mg.kg‐1) - Combination of wound infiltration and regional nerve blockade (Group C)
Study: 30290765
Drug: Modified Robert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Robert Jones bandage (MRJB) compression therapy for 24 hours
Study: 30290765
Drug: No compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: No compression therapy (Control)
Study: 27237764
Drug: mSMT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mSMT treatment
Study: 24501162
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day saffron
Study: 20004276
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg intraamniotic (1.0 IA)
Study: 20004276
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg intrafetal (1.0 IF)
Study: 20004276
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg intraamniotic (1.5 IA)
Study: 20004276
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg intrafetal (1.5 IF)
Study: 12832959
Drug: Abstinence with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence with transdermal nicotine patch (25 mg per day)
Study: 20347467
Drug: Abstinence with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence with placebo patch
Study: 8849265
Drug: Subcutaneous rhG‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rhG‐CSF (lenograstim, 2 micrograms per kg of body weight per day)
Study: 1462489
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered estriol at a dose of 0.01 g daily for 3 weeks, and 0.01 g bi‐weekly for a further 3 weeks
Study: 1462489
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered estriol
Study: 30326906
Drug: Self-management exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management exercise program + spa therapy (5 sessions of self-management exercise, 18 sessions of spa therapy)
Study: 30326906
Drug: Information booklet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information booklet + spa therapy (18 sessions of spa therapy)
Study: 30326906
Drug: Self-management exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management exercise program + spa therapy
Study: 22569484
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg vaccine
Study: 22569484
Drug: 120 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 μg vaccine
Study: 22569484
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg vaccine
Study: 20353751
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (20 mg leflunomide)
Study: 18300351
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of H pylori-positive patients and all H pylori-positive family members (group I)
Study: 12566476
Drug: Protein Group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Group consuming a diet with a CHO/protein ratio of 1.4 (125 g protein/d)
Study: 9346692
Drug: Control interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control interval (no drug)
Study: 1678797
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (laxatives plus behaviour modification)
Study: 27825009
Drug: Anakinra (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (2 mg/kg per day, up to 100 mg for 2 months)
Study: 24188873
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist
Study: 24188873
Drug: Short GnRH
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short GnRH agonist
Study: 9398894
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Metronidazole 400 mg + Clarithromycin 500 mg (OMC500)
Study: 9398894
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Amoxicillin 1 gm + Clarithromycin 250 mg (OAC250)
Study: 9398894
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Amoxicillin 1 gm + Metronidazole 400 mg (OAM)
Study: 9398894
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Placebo (OP)
Study: 3872061
Drug: Casein hydrolysate
Normalized name: casein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein hydrolysate preparation
Study: 3872061
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake formulas (4.3 g/kg/day and 4.4 g/kg/day)
Study: 24062326
Drug: Fixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed meal dosing
Study: 24062326
Drug: Flexible meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible meal dosing
Study: 22029980
Drug: Briakinumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Briakinumab (200 mg at weeks 0 and 4, 100 mg at week 8 and every 4 weeks thereafter)
Study: 22029980
Drug: Methotrexate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (5 to 25 mg weekly)
Study: 16937305
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin (CDDP) at 50 mg/m(2) for monthly schedule
Study: 11598313
Drug: Clioquinol 20
Normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clioquinol 20 mg/day
Study: 11598313
Drug: Clioquinol 80
Normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clioquinol 80 mg/day
Study: 9531122
Drug: Continuous-flow cold
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-flow cold therapy for 3 days, then as needed for days 4-7.
Study: 7758059
Drug: Diclofenac dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dispersible 50 mg
Study: 2783753
Drug: Predonation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predonation of autologous blood and isovolumetric substitution of hydroxyethyl starch (10 ml/kg bodyweight) after induction of anesthesia plus cell separator (Group III)
Study: 12518131
Drug: No rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rectal tube insertion
Study: 12929752
Drug: Intraoperative photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative photodynamic therapy (PDT)
Study: 31605493
Drug: Daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of rhEPO combined with iron supplement starting 3 days before surgery (Group A)
Study: 29095982
Drug: 40 U
Normalized name: lipase 10440 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 U insulin spray
Study: 29095982
Drug: 80 U
Normalized name: lipase 20880 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 U insulin spray
Study: 21041815
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of clear apple juice
Study: 21041815
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of clear apple juice without polyphenols (placebo)
Study: 21041815
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of cloudy apple juice (positive control)
Study: 18846024
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg, single dose)
Study: 16248381
Drug: Technetium‐99m DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technetium‐99m DTPA aerosol inhalation scintigraphy
Study: 8580273
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg
Study: 18435833
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg
Study: 28351201
Drug: Active electroconvulsive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active electroconvulsive therapy
Study: 28351201
Drug: Sham electroconvulsive
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroconvulsive therapy
Study: 20652288
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg oral misoprostol
Study: 20652288
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg sublingual misoprostol
Study: 20298399
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (salmeterol/fluticasone propionate)
Study: 16621879
Drug: Torasemide (4‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (4‐8 mg/day; n = 20)
Study: 16621879
Drug: Furosemide (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20‐40 mg/day; n = 20)
Study: 10360914
Drug: Control cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycle (before treatment)
Study: 1937993
Drug: Adalat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalat (10 mg capsules)
Study: 1937993
Drug: Nifecard (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifecard (10 mg capsules)
Study: 6814596
Drug: Transaxial tomoscintigraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transaxial tomoscintigraphy using iodine‐131‐labelled monoclonal antibodies against carcinoembryonic antigen
Study: 18042798
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone
Study: 25529014
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HI-CT)
Study: 1312233
Drug: Lisinopril +
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril + Hydrochlorothiazide (LIS + HCTZ)
Study: 3900906
Drug: Calf lung
Normalized name: Calf lung surfactant extract (CLSE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf lung surfactant extract (3 mL, 90 mg) instilled into trachea before the first breath
Study: 27055228
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using a 660-nm laser (200 mW, 6 J per point at 4 points) and an 810-nm laser (200 mW, 6 J per point at 3 points) applied on days 2 and 4 after surgery
Study: 25646296
Drug: Azilsartan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan 20 mg
Study: 17943639
Drug: Desmopressin tablets
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablets and nasal spray
Study: 25213159
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus supportive care
Study: 14741163
Drug: ALVAC-HIV vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV vaccines
Study: 14741163
Drug: ALVAC-HIV vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV vaccines with recombinant envelope subunit vaccine
Study: 10052667
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion for 1 hour
Study: 28689794
Drug: SQ grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ grass sublingual immunotherapy tablet
Study: 23913463
Drug: SIELLO T
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIELLO T steroid‐eluting ventricular leads
Study: 23913463
Drug: SIELLO JT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIELLO JT steroid‐eluting atrial leads
Study: 23913463
Drug: BPPU T
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPPU T non‐steroid leads
Study: 23913463
Drug: BPPU JT
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPPU JT non‐steroid leads
Study: 12579548
Drug: Self-administered psychosocial
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered psychosocial treatments (manual- and multimedia-based treatments)
Study: 12579548
Drug: Self-administered psychosocial
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered psychosocial treatments (inspirational literature and support groups)
Study: 10731864
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (1 mg/kg/d) (Group B)
Study: 12969204
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 3 mg/kg
Study: 3527997
Drug: Arginine tidiacicate
Normalized name: arginine tidiacicate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine tidiacicate (ATCA) at a dose of 400 mg tablets three times a day for 30 days
Study: 2659736
Drug: Cyclosporin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (mean dose 7.2 mg/kg/day)
Study: 2659736
Drug: Cyclosporin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (mean dose 5 mg/kg/day)
Study: 24420962
Drug: THC/CBD spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD spray
Study: 12151445
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified urinary FSH (150 IU starting dose)
Study: 12151445
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg/day from day 5-10 of the ovarian cycle)
Study: 12151445
Drug: FSH after
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH after failure with CC
Study: 12151445
Drug: CC followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC followed by FSH if pregnancy not obtained
Study: 9471040
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg daily
Study: 30897305
Drug: Ibuprofen lysinate
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysinate (postprandial)
Study: 8614572
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ritanserin
Study: 10803508
Drug: Initial systemic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial systemic chemotherapy (prednisone, vincristine, doxorubicin, cyclophosphamide)
Study: 8628601
Drug: Antenatal phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal phenobarbital (PB) therapy
Study: 8628601
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PB therapy)
Study: 29754812
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical therapy (control, n=86)
Study: 25590178
Drug: Somatostatin 250μg
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 250μg bolus injection before ERCP and 250μg/hour intravenous infusion for 11 hours after ERCP
Study: 22790176
Drug: VRET with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRET with cognitive therapy
Study: 20564068
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of oral modafinil daily
Study: 16301017
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments (behavioural, cognitive-behavioural, cognitive)
Study: 23663490
Drug: Pharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatments
Study: 3923855
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 20 mg inhaled four times a day for 2 months
Study: 3923855
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg orally twice a day for 2 months
Study: 3923855
Drug: Clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 1 mg orally twice a day for 1 week
Study: 3923855
Drug: Placebo (lactose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose) capsule twice a day for 2 months